Sporanox to be avoided in heart failure

15 December 2005

The antifungal agent Sporanox (itraconazole) should not be used in patients with congestive heart failure or a history of congestive heart failure unless the benefit clearly outweighs the risk.

The warning follows observations that Sporanox exerts a negative inotropic effect, and reports of congestive heart failure associated with its use.

If the benefits do exceed the risk of using Sporanox in patients with heart failure, such patients should be monitored closely and the drug discontinued if symptoms of heart failure develop.

View Sporanox drug record

Further Information: Janssen-Cilag Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

The most up-to-date drug information at your fingertips.

  • Get the prescribing support you need.
  • Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Register Now
Already Registered?

Forgotten password?

More from MIMS

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

An empty tablet blister pack.

Ezetimibe supply update

Availability issues have been reported for the lipid-lowering...

Woman holding blister strip of contraceptive pills

Pharmacists across England to initiate oral contraceptives

Pharmacy Contraception Service (PCS) could allow almost...